Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

5.980 -0.010 (-0.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,726,777
Open 5.700
Bid (Size) 5.900 (200)
Ask (Size) 6.100 (5,000)
Prev. Close 5.990
Today's Range 5.420 - 6.070
52wk Range 3.840 - 11.50
Shares Outstanding 48,518,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Personalis Q1 Earnings Call Highlights ↗
Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business... 
Via MarketBeat
Topics Earnings
News headline image
Personalis (PSNL) Q1 2026 Earnings Transcript ↗
Personalis (PSNL) Q1 2026 Earnings Transcript 
Via The Motley Fool

Performance

YTD
-23.8%
-23.8%
1 Month
-3.1%
-3.1%
3 Month
-19.4%
-19.4%
6 Month
-16.8%
-16.8%
1 Year
+23.6%
+23.6%

More News

Read More
Personalis (NASDAQ:PSNL) Volume Surge Can't Mask Q1 Miss as Losses Widen ↗
Via Chartmill
News headline image
Personalis Reports First Quarter Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
Personalis Inc (NASDAQ:PSNL) Reports Mixed Q4 2025 Results and Aggressive 2026 Growth Outlook ↗
Via Chartmill
News headline image
Personalis to Announce First Quarter 2026 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the 25th Annual Needham Virtual Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
From Personalis, Inc.
Via Business Wire
News headline image
Lightspeed Makes a Big Bet on Self-Driving Trucks, Loading Up on 7 Million Shares of Kodiak AI (KDK) ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Lightspeed Management Made a Huge Bet on Navan (NAVN) With a Purchase of 49.9 Million Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Personalis (PSNL) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
From Personalis, Inc.
Via Business Wire
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
From Personalis, Inc.
Via Business Wire
News headline image
AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares ↗
Via The Motley Fool
News headline image
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Personalis, Inc.
Via Business Wire

Frequently Asked Questions

Is Personalis, Inc. - Common Stock publicly traded?
Yes, Personalis, Inc. - Common Stock is publicly traded.
What exchange does Personalis, Inc. - Common Stock trade on?
Personalis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Personalis, Inc. - Common Stock?
The ticker symbol for Personalis, Inc. - Common Stock is PSNL on the Nasdaq Stock Market
What is the current price of Personalis, Inc. - Common Stock?
The current price of Personalis, Inc. - Common Stock is 5.980
When was Personalis, Inc. - Common Stock last traded?
The last trade of Personalis, Inc. - Common Stock was at 05/08/26 04:00 PM ET
What is the market capitalization of Personalis, Inc. - Common Stock?
The market capitalization of Personalis, Inc. - Common Stock is 290.14M
How many shares of Personalis, Inc. - Common Stock are outstanding?
Personalis, Inc. - Common Stock has 290M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.